Archives
-
10 mM dNTP Mixture for Reliable DNA Workflows
2026-08-28
Build reproducible PCR, qPCR, sequencing, and DNA-tracking workflows with a ready-to-use equimolar nucleotide source. This guide connects practical dNTP handling with a 2025 study showing how cholesterol can impede lipid nanoparticle trafficking, while clearly separating established reagent use from emerging delivery research.
-
Leucovorin Calcium in Gastric Cancer Assembloids
2026-08-28
Leucovorin Calcium, also known as calcium folinate, offers translational researchers a mechanistically grounded way to study methotrexate rescue within patient-derived gastric cancer assembloids. By combining folate pathway perturbation with matched tumor and stromal models, researchers can move beyond simple viability readouts toward more informative analyses of microenvironment-dependent response and antifolate resistance.
-
Protease Inhibitor Cocktail for Protein Workflows
2026-08-27
Protect labile targets such as METTL3, HSP90, and MYC-associated complexes from ex vivo proteolysis during lysis, Western blotting, and co-immunoprecipitation. This two-component format combines broad-spectrum protease inhibition with separate EDTA, allowing researchers to include or remove metalloprotease protection according to downstream assay chemistry.
-
Lipo3K Transfection Reagent for APOL1 Studies
2026-08-27
Build cleaner APOL1 isoform, variant, and APOL3 interaction assays with a low-toxicity lipid transfection reagent. This workflow combines plasmid enhancement, siRNA optimization, and viability controls for difficult cell models.
-
EZ Cap™ Cy5 EGFP mRNA: Uptake to Expression
2026-08-26
A translational framework for using dual-fluorescence reporter mRNA to separate cellular delivery from productive translation, validate nanoparticle design, and improve the interpretability of gene regulation and function studies.
-
IDO1 Blockade and Tumor-Protective JAK2/STAT3 Signaling
2026-08-26
The reference study shows that pharmacological IDO1 inhibition can activate antitumor immune cells while simultaneously inducing an IL-6–JAK2–STAT3 survival program within tumor cells. Its single-cell analysis supports combining IDO1 blockade with pathway-directed intervention, while also highlighting the limits of interpreting immune activation without resolving tumor-intrinsic responses.
-
ONX-0914: Translational Immunoproteasome Strategy
2026-08-25
A thought-leadership guide to using ONX-0914 (PR-957) as a selective immunoproteasome perturbation tool, connecting LMP7 biology with cytokine control, autoimmune disease models, and emerging proteasome heterogeneity research in breast cancer.
-
Dronedarone (Multaq) Research Workflows
2026-08-25
Build reproducible Dronedarone workflows for atrial fibrillation, atrial flutter, ion-channel, and CYP interaction studies. This guide combines solvent-aware handling, automated patch-clamp assay design, exposure matching, and troubleshooting for stronger cardiac arrhythmia pharmacology data.
-
Tamoxifen Workflows for CreER and Cancer Research
2026-08-24
Tamoxifen supports both temporal genetic recombination and mechanistically informed cancer assays, but its estrogen-receptor activity can create important off-target phenotypes. This practical guide connects stock preparation, controls, dose design, and troubleshooting to reproducible CreER-mediated gene knockout and cell-based workflows.
-
JHU-083 for Reliable Glutaminase Assays
2026-08-24
A scenario-driven guide to using JHU-083 (SKU BA7770) in viability, proliferation, cytotoxicity, and glutaminase-pathway experiments. It covers mechanism, solvent compatibility, stock preparation, assay interpretation, and practical vendor-selection criteria for biomedical laboratories.
-
CAR Macrophage Programming for Peritoneal Metastasis
2026-08-23
Gu and colleagues developed a macrophage-targeted mRNA lipid nanoparticle platform that programs CAR macrophages directly in the peritoneal cavity and systematically compared 36 CAR designs. The leading CD3ζ–TLR4 configuration reshaped the tumor microenvironment, increased progenitor-exhausted CD8+ T-cell activity, and enhanced the response to PD-1/L1 checkpoint therapy.
-
From Acid Mucins to Translational Readouts
2026-08-22
A mechanistic and strategic guide to using dual Alcian Blue and Nuclear Fast Red staining for mucopolysaccharide detection, chondrogenic differentiation studies, and more defensible translational workflows.
-
Nitrocefin: From Color Shift to Inhibitor Insight
2026-08-22
Nitrocefin is a chromogenic cephalosporin substrate that converts β-lactamase activity into a measurable color signal. This article explains how to move beyond simple detection by using Nitrocefin kinetics to validate computationally identified inhibitors and interpret antibiotic-resistance experiments more rigorously.
-
How p38α Conformation Controls Dephosphorylation
2026-08-21
The preprint Dual-Action Kinase Inhibitors Influence p38α MAP Kinase Dephosphorylation shows that selected inhibitors can both suppress p38α catalytic activity and accelerate removal of its activation-loop phosphate by WIP1. Its biochemical and X-ray structural analyses provide a framework for designing kinase inhibitors that control phosphatase access, although the findings remain primarily mechanistic and preclinical.
-
Nuclear cGAS–Chk2 Control of L1 Retrotransposition
2026-08-20
The reference study identifies a nuclear genome-protection pathway in which DNA damage activates Chk2, phosphorylated cGAS recruits TRIM41, and TRIM41 ubiquitinates and destabilizes L1 ORF2p. This mechanism expands cGAS biology beyond cytosolic innate immune signaling and provides a framework for studying retrotransposon control in genome instability, aging, and cancer research.